Hyperglycemia and dyslipidemia are common metabolic abnormalities in adults with type 1 diabetes mellitus (T1DM) and both increase cardiovascular disease risk. Normalization of lipid metabolism is a mandatory element in preven-tion of diabetic micro- and macroangiopathies in patients with T1DM and it is directly related to improvement of health outcome. We aimed to investigate serum lipid profiles in patients with T1DM and poor glycemic control. Among observed patients with T1DM, 76% were classified as having dyslipidemia, dyslipidemia rate was higher in patients with diabetic microangiopathies. Patients with T1DM and microvascular complications, arterial hypertension (AH) and the level of glycated hemoglobin (HbA1c) >8% had significantly higher levels of total cholesterol (TC), very low density lipoproteins (VLDL), triglycerides (TG) and non-high density lipoproteins (non-HDL). Therefore, management of patients with T1DM at the outpatient stage requires a strict control of lipid metabolism.
diabetes mellitus, dyslipidemia, cholesterol, HDL, LDL, VLDL, triglycerides, non-HDL
1. DedovII, ShestakovaMV (eds.) (2015). Standards of specialized diabetes care [Algoritmy spetsializirovannoy meditsinskoy pomoshchi bol’nym sakharnym diabetom (7-y vypusk)]. Sakharnyy diabet, 18(1S), 112.
2. DedovII, ShestakovaMV (eds.) (2012). Diabetes mellitus: acute and chronic complications [Sakharnyy diabet: ostrye i khronicheskie oslozhneniya],480.
3. SamoylovaYG, YurchenkoEV (2014). Features of lipid metabolism in patients with type 1 diabetes, depending on diabetic microvascular complications and diet [Osobennosti lipidnogo obmena u patsientov s sakharnym diabetom 1-go tipa v zavisimosti ot nalichiya diabeticheskikh mikroangiopatiy i kharaktera pitaniya]. Byulleten’ sibirskoy meditsiny, (5) 87-92
4. ACCORD Study Group and ACCORD Eye Study Group. (2012). Effects of medical therapies on retinopathy progression in type 2 diabetes. N.Engl. J.Med., 367(25), 2458.
5. American Diabetes Association (2014). Executive summary: Standards of medical care indiabetes - 2014. Diabetes Care, 37(1), 5-13.
6. ChowdhuryTA, HopkinsD, DodsonPM, VafidisGC (2002). The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy? Eye (Lond.), 16(6), 689-693.
7. DaaeLN, VierultP, LandaasS, UrdalP (1993). Cardiovascular risk factors: interactive effect of lipids, coagulation and fibrinolysis. Scand.J.Clin.Lab.Invest.,(215), 19-27.
8. Expert Dyslipidemia Panel, GrundySM (2013). An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. J. Clin. Lipidol., 7(6), 561-565
9. HoffinerSM (1993). Lipoprotein (a) and diabetes. An update. Diabetes Care, (16), 835-843.
10. KeechAC, MitchellP, SummanenPA, O’DayJ,DavisTM, MoffittMS, TaskinenMR, SimesRJ, TseD,WilliamsonE, MerrifieldA, LaatikainenLT, d’EmdenMC,CrimetDC, O’ConnellRL, ColmanPG, FIELD study investigators. (2007). Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet, 370(9600), 1687-1697.
11. KhawKT, WarehamN, BinghamS, LubenR, WelchA, DayN (2004). Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann. Intern. Med., (141), 413-420.
12. KimSH, JungIA, JeonYJ, ChoWK, ChoKS, ParkSH,JungMH, SuhBK (2014). Serum lipid profiles and glycemic control in adolescents and young adults with type 1 diabetes mellitus. Ann. Pediatr. Endocrinol. Metab., (19), 191-196
13. MaahsDM, OgdenLG, DabeleaD (2010).Association of glycaemia with lipids in adults with type 1 diabetes: modification by dyslipidaemia medication. Diabetologia, 53(12), 2518-2525.
14. MuntnerP, CoreshJ, SmithJC, EckfeldtJ, KlagMJ (2000). Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int., 58(1), 293-301.
15. ThomasMC, Rosengard-BarlundM, MillsV,RönnbackM, ThomasS, ForsblomC, CooperME,TaskinenMR, VibertiG, GroopPH (2006). Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care, 29(2), 317-322
